Why the study?
Double heterozygosity for LDLR, APOB, or PCSK9 causes a more severe ADH phenotype, and APOE was recently identified as a causative ADH gene, prompting investigation into the phenotype of double heterozygotes for rare LDLR and APOE variants.
Does double heterozygosity for rare LDLR and APOE variants worsen the lipid profile and increase the risk of premature atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia?
Does double heterozygosity for rare LDLR and APOE variants worsen the lipid profile and increase the risk of premature atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia?
The presence of rare APOE variants in addition to LDLR variants has an additive deleterious effect on the familial hypercholesterolemia phenotype, resulting in significantly higher LDL-C levels and increased risk of premature cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Characterizes rare LDLR+APOE double heterozygote phenotypes in ADH; leaves open whether APOE variants modify severity in larger cohorts.
Background: Autosomal dominant hypercholesterolemia (ADH) is due to deleterious variants in LDLR , APOB , or PCSK9 genes. Double heterozygote for these genes induces a more severe phenotype. More recently, a new causative variant of heterozygous ADH was identified in APOE . Here we study the phenotype of 21 adult patients, double heterozygotes for rare LDLR and rare APOE variants ( LDLR+APOE ) in a national wide French cohort. Methods: LDLR , APOB , PCSK9 , and APOE genes were sequenced in 5743 probands addressed for ADH genotyping. The lipid profile and occurrence of premature atherosclerotic cardiovascular diseases were compared between the LDLR+APOE carriers (n=21) and the carriers of the same LDLR causative variants alone (n=22). Results: The prevalence of LDLR+APOE carriers in this French ADH cohort is 0.4%. Overall, LDL (low-density lipoprotein)-cholesterol concentrations were 23% higher in LDLR+APOE patients than in LDLR patients (9.14±2.51 versus 7.43±1.59 mmol/L, P=0 .0221). When only deleterious or probably deleterious variants were considered, the LDL-cholesterol concentrations were 46% higher in LDLR+APOE carriers than in LDLR carriers (10.83±3.45 versus 7.43±1.59 mmol/L, P=0 .0270). Two patients exhibited a homozygous familial hypercholesterolemia phenotype (LDL-cholesterol >13 mmol/L). Premature atherosclerotic cardiovascular disease was more common in LDLR+APOE patients than in LDLR carriers (70% versus 30%, P=0 .026). Conclusions: Although an incomplete penetrance should be taken into account for APOE variant classification, these results suggest an additive effect of deleterious APOE variants on ADH phenotype highlighting the relevance of APOE sequencing.
No takes yet. Share an insight, caveat, or question.
Marmontel et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: